Sysmex Europe

Sysmex joins the global fight against AMR

Sysmex joins the global
fight against AMR


83% of patients may not receive any urinalysis testing before getting an antibiotic prescription [1]. The antibiotic regime is then started before conclusive evidence that they’re needed.


Urinary tract infection is the most frequent bacterial infection amongst women, with recurrent infections being a problem for 25–30% of women who experience an initial infection [2].


In 2019, an estimated 4.95 million deaths were associated with drug-resistant infections, with urinary tract infections being in the top four infectious syndromes [3].

The next big move

in hindering AMR

The antibiotic susceptibility testing method

Antibiotic susceptibility testing (AST) is performed in order to identify which antimicrobial regimen is specifically effective for individual infections [4]. Phenotypic antibiotic susceptibility tests are typically based on the detection of differential bacterial growth with and without antibiotics in liquid cultures or on solid agar plates [5]. Any AST method used is generally reliable for detecting resistance and determining the antibiotic concentration that prevents bacterial growth, however, because it can take one to two days to get reliable results, these methods are not ideal when guiding treatment in the early and critical stages of infection [6].

New phenotypic AST methodologies

Traditional AST methods focus on the genotypic approach, however, to produce results that offer the maximum added value for the attending physician, efforts have shifted towards the development of new phenotypic AST methodologies. Nanofluidics-based AST is classified as a phenotypic method because the result depends on the actual resistance profile, and enables us to generate results in real time based on bacterial cell growth [7].

Nanofluidics-based AST technology at the point of care

The nanofluidics-based AST technology will be the basis for innovated lab-on-a-chip diagnostic devices that can be used directly at the point of care. For everyday infections, the possibility of a near-patient testing device provides a unique tool to select antibiotics tailored to each infectious episode. Making this information available to the treating expert and so close to the patient is key in the fight against AMR.

Want to know more about AST? Read "rethinking routine antibiotic susceptibility testing"

Rule out UTI

in less than a minute

with modern diagnostics

Fighting AMR doesn’t

stop here...

AMR Video series

AMR Video series

Antimicrobial resistance can pop up in our lives from everyday situations. Watch our video series and learn how you can implement simple habits in your life that can help fight AMR.

How AMR is affecting health care in Japan

How AMR is affecting health care in Japan

Learn how AMR is affecting health care settings in Japan in this interview with urologist Prof. Yamamoto. He and his team are working on analysing E. coli, the most common bacteria in UTIs. Read here.

AMR Quiz

AMR Quiz

Think you know the basics about antimicrobial resistance? Test your knowledge here and solidify your rank as an AMR fighter.

Infectious diseases

Infectious diseases

Health care professionals must make difficult therapy decisions every day based on the latest clinical evidence. Explore how Sysmex is supporting them with knowledge on infectious diseases.



With a quick malaria diagnosis, targeted treatment can be started more quickly, thereby limiting the unnecessary use of antimalarials. Find out how an accurate malaria diagnosis boosts the fight against AMR for malarials.

Copyright © Sysmex Europe SE. All rights reserved.